Key Takeaways
- Vetigenics, a Philadelphia-based biotechnology firm, secured $6M in Seed funding.
- Funds will support clinical trials and the advancement of its proprietary CANIBODY™ technology for targeted antibody therapies in pets.
- The company is nearing key milestones in trials for canine cancer therapies VGS-001 and VGS-002.
Funding and Future Plans
Vetigenics, a clinical-stage animal health biotechnology company located in Philadelphia, has successfully raised $6 million in Seed funding to further its operations. The details of the backers remain undisclosed, but the funding aims to propel the company’s clinical-stage programs toward pivotal trials, expedite preclinical candidates, and enhance manufacturing capabilities.
Led by Adriann Sax, President and CEO, and Nicola Mason, a co-founder and clinical investigator, Vetigenics focuses on developing targeted antibody therapies for pet health. The company’s unique CANIBODY™ technology is designed to create effective antibodies that address various health issues in pets, drawing from successful treatments used in human medicine for cancer and chronic diseases. Vetigenics also collaborates with international animal health partners and the National Cancer Institute to expand its reach and expertise in antibody discovery and development.
Vetigenics is making notable progress in two significant trials for canine cancer treatments:
– **VGS-001 (anti-cCTLA4)**: This therapy, combined with palliative radiation, targets oral melanoma in dogs. The trial has concluded, and results are expected to be published in 2025, pending encouraging findings.
– **VGS-002 (anti-cPD1)**: This treatment is being evaluated as a standalone therapy for dogs with urothelial carcinoma, nearing completion with promising results anticipated in the near future.
To navigate its growth trajectory, Vetigenics has established a board of directors comprising influential figures in the industry. This board includes Chand Khanna, DVM, PhD, known for his expertise in comparative oncology; Stephen Lesser, JD, MBA, a strategic advisor in biotechnology; and Caleb Frankel, VMD, recognized for innovations in veterinary technology. Adriann Sax, the company’s CEO, also serves on this board.
With the recent funding and a strong leadership team, Vetigenics is poised for significant advancements in the field of pet health, focusing on transformative therapies that could improve the quality of life for pets battling cancer and other chronic conditions.
The content above is a summary. For more details, see the source article.